Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world evidence from China: Clinical characteristics, treatment landscape and long-term outcomes in 566 autoimmune hemolytic anemia patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JQJiewen QiuJSJun ShiXZXin Zhao

Discussion

Loading...

Member takes

Overview

Retrospective cohort study highlights clinical features and response rates in autoimmune hemolytic anemia, suggesting risk factors for long-term outcomes.

Key Points

  • This study aims to characterize the clinical features and treatment patterns of autoimmune hemolytic anemia and assess long-term outcomes.
  • Retrospective cohort study of 566 AIHA patients from a single center in China.
  • Analysis of clinical, laboratory characteristics, and treatment responses.
  • Survival analyzed using Kaplan-Meier and Cox regression models.
  • Observed 1-, 3-, and 5-year overall survival rates of 96%, 92%, and 89%.
  • Identified independent mortality risk factors including age ≥60, glucocorticoid non-response, and opportunistic infections.
  • Noted secondary forms prevalent in mixed AIHA and treatment response rates of 92.3% for warm AIHA and 97.3% for mixed AIHA.

Cite This Study

Qiu et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cf86https://doi.org/10.1182/blood-2025-2878
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Who needs second-line therapy? predictors of sustained response in autoimmune hemolytic anemia2025
  2. 2Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis2025
  3. 3Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders2026
  4. 4The prognostic implications of autoimmune hemolytic anemia in chronic lymphocytic leukemia across treatment eras2026
  5. 5Severe Warm Autoimmune Hemolytic Anemia With Profound Anemia Requiring Multimodal Immunosuppressive Therapy2026